Medline Inc. is being investigated by Kirby McInerney LLP for potential federal securities-law violations and other unlawful business practices after an FDA warning identified significant Current Good Manufacturing Practice violations. The warning cited failures to thoroughly investigate unexplained discrepancies or batch failures. Medline shares fell 7.2% on June 2, 2026, after the warning became public, and another 12.8% on Aug. 5 after the company disclosed that remediation measures, including removing products from the market, had resulted in earnings loss. No lawsuit has been filed, and the investigation remains ongoing.